denkapparat Operations GmbH Purchases Shares of 9,416 Lantheus Holdings, Inc. $LNTH

denkapparat Operations GmbH purchased a new stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 9,416 shares of the medical equipment provider’s stock, valued at approximately $1,045,000.

Several other large investors also recently made changes to their positions in LNTH. Western Wealth Management LLC acquired a new stake in shares of Lantheus during the first quarter worth $25,000. Smartleaf Asset Management LLC boosted its stake in Lantheus by 63.3% in the 4th quarter. Smartleaf Asset Management LLC now owns 508 shares of the medical equipment provider’s stock worth $34,000 after purchasing an additional 197 shares during the period. Parallel Advisors LLC boosted its stake in Lantheus by 122.6% in the 4th quarter. Parallel Advisors LLC now owns 541 shares of the medical equipment provider’s stock worth $36,000 after purchasing an additional 298 shares during the period. Osterweis Capital Management Inc. bought a new position in Lantheus during the 2nd quarter worth about $36,000. Finally, Bessemer Group Inc. raised its stake in shares of Lantheus by 221.2% in the 1st quarter. Bessemer Group Inc. now owns 514 shares of the medical equipment provider’s stock valued at $39,000 after purchasing an additional 354 shares during the period. Institutional investors own 99.06% of the company’s stock.

Lantheus Stock Up 0.2%

Shares of LNTH stock opened at $100.98 on Friday. The company has a current ratio of 3.06, a quick ratio of 2.89 and a debt-to-equity ratio of 0.43. Lantheus Holdings, Inc. has a 1 year low of $49.67 and a 1 year high of $111.86. The firm’s fifty day moving average price is $103.29 and its two-hundred day moving average price is $92.69. The firm has a market capitalization of $6.59 billion, a P/E ratio of 24.39 and a beta of -0.03.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings results on Thursday, August 6th. The medical equipment provider reported $1.55 EPS for the quarter, topping the consensus estimate of $1.30 by $0.25. Lantheus had a net margin of 17.69% and a return on equity of 28.10%. The firm had revenue of $388.18 million for the quarter, compared to analysts’ expectations of $363.23 million. During the same period in the previous year, the firm posted $1.57 EPS. The company’s revenue for the quarter was up 2.7% on a year-over-year basis. On average, equities analysts predict that Lantheus Holdings, Inc. will post 4.48 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the company. Wall Street Zen lowered Lantheus from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. Weiss Ratings upgraded Lantheus from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday, August 27th. Leerink Partners set a $102.50 target price on Lantheus in a research report on Monday, August 3rd. Mizuho cut their target price on Lantheus from $120.00 to $115.00 and set an “outperform” rating on the stock in a research note on Wednesday, July 29th. Finally, Citizens Jmp restated a “market outperform” rating and issued a $115.00 target price on shares of Lantheus in a research note on Monday, June 29th. Four investment analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $108.11.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.